New combo therapy aims to stall Hard-to-Treat prostate cancer
NCT ID NCT07451795
First seen Mar 10, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This Phase 2 trial is testing whether combining an experimental immunotherapy drug (SHR-1701) with targeted radiation can help men whose prostate cancer has spread and stopped responding to hormone therapy. About 66 participants will receive either the combination or radiation alone. The main goal is to see how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Fudan University Shanghai Cancer Center Xiamen Branch
RECRUITINGXiamen, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Fujian Cancer Hospital
RECRUITINGFujian, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-1701 (an experimental immunotherapy drug) plus stereotactic body radiotherapy (focused radiation)
What this could lead to
If successful, this combination could offer a new treatment option to slow disease progression in men with advanced prostate cancer that no longer responds to hormone therapy.
What could go wrong
This is an early-phase (Phase 2) trial with only 66 participants, so results may not apply to all patients. The immunotherapy SHR-1701 is experimental and may cause immune-related side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.